Rasagiline Mesylate
CAS No. 161735-79-1
Rasagiline Mesylate( —— )
Catalog No. M12364 CAS No. 161735-79-1
Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 34 | In Stock |
|
| 50MG | 41 | In Stock |
|
| 100MG | 65 | In Stock |
|
| 200MG | 87 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRasagiline Mesylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionRasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.
-
DescriptionRasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.(In Vitro):Rasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment.(In Vivo):Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy.
-
In VitroRasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment.Cell Viability Assay Cell Line:Neuroblastoma SH-SY5Y, and glioblastoma 1242-MG Concentration:0.25 nM Incubation Time:96 hours Result:Caused ~60% increase in the cell proliferation rate for SH-SY5Y cells treated with Dexamethasone.Caused ~35% increase in cell proliferation rate for 1242-MG cells treated with Dexamethasone.
-
In VivoRasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy. Animal Model:(PLP)-α-synuclein transgenic mice over 6 months of age Dosage:Low-(0.8 mg/kg b.w.) and high dose (2.5 mg/kg b. w.) Administration:Administered subcutaneously every 24 h for a total period of 4 weeks (from day 1 till day 28 of the experiment). Result:Low dose treatment did not show protective efficacy in striatum with number of neurons similar to placebo treated MSA mice. High dose was associated with about 15% rescue of DARPP-32 immunoreactive striatal neurons.Low dose treatment had no effect on nigral neuronal loss, but high dose completely protected nigral neurons with numbers comparable to healthy controls.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetMAO
-
RecptorMAO-A| MAO-B
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number161735-79-1
-
Formula Weight267.34
-
Molecular FormulaC13H17NO3S
-
Purity>98% (HPLC)
-
SolubilitySoluble in water
-
SMILESCS(=O)(=O)O.C#CCN[C@@H]1CCC2=CC=CC=C12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Youdim MB, et al. Br J Pharmacol, 2001, 132(2), 500-506.
molnova catalog
related products
-
Nialamide
An MAO inhibitor that is used as an antidepressive agent.
-
Hydroxyamine hydroch...
Hydroxyamine hydrochloride(Hydroxylammonium chloride) is a selective and potent monoamine oxidase (MAO) inhibitor with inhibitory effects on platelet aggregation.
-
RS 8359
RS 8359 is a reversible inhibitor of monoamine oxidase A (MAO-A) with a selectivity ratio of about 2200 for the A:B enzyme types.
Cart
sales@molnova.com